CEO and CFO Ronan Kennedy attributed the revenue growth to a 61% surge in wholesale net sales and the expansion of the Oasis beverage brand, which recently introduced a zero-proof kava product. Despite the growth, the company faced a bottom-line shortfall, which Kennedy described as a result of deliberate strategic choices. These included absorbing one-time expenses related to M&A due diligence, product development, and the resolution of supply-chain and state-level compliance issues.

To improve fiscal flexibility, the company implemented cost-reduction initiatives in July aimed at saving up to $150,000 per month. Looking toward the federal landscape, cbdMD is preparing for the November 12, 2026, effective date of H.R. 5371, Section 781. Management expressed optimism regarding a potential legislative extension and the introduction of bipartisan proposals like the Beverage Regulatory Parity Act, which could establish a clearer framework for hemp-derived beverages. With Bluebird Botanicals expected to contribute to earnings in the fourth quarter, the company aims to leverage its compliance-focused positioning to navigate the evolving regulatory environment.